CorMedix Inc. 8-K

What Happened

• CorMedix Inc. filed an 8-K on March 6, 2026 (Item 7.01) to furnish an updated investor presentation (Exhibit 99.1) and to reaffirm prior guidance. The company confirmed its full-year 2027 DefenCath sales estimate of $100 million to $140 million, as originally provided in its January 8, 2026 press release. CorMedix said an inadvertent reference on its March 5, 2026 earnings call to a $100 million to $125 million range was incorrect.

Key Details

• Reaffirmed 2027 DefenCath sales guidance: $100 million to $140 million (full year).
• Original guidance announced: January 8, 2026 press release.
• Inadvertent misstatement on earnings call: March 5, 2026 referenced $100M–$125M (now corrected).
• Updated investor presentation furnished as Exhibit 99.1 with the 8-K filed March 6, 2026.

Why It Matters

• For investors, the reaffirmation clarifies management’s sales expectations for DefenCath in 2027, which is a key driver of CorMedix’s future revenue outlook. Correcting the discrepancy from the March 5 earnings call reduces confusion for analysts and investors updating revenue models or valuation assumptions. The filing does not report new financial results—rather, it provides published guidance and an updated investor presentation.